Ralph M. Wirtz

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 136 publications

Management and decision-making after implantation of a non-sterilized implant in a trauma patient.

Management and decision-making after implantation of a non-sterilized implant in a trauma patient.

Journal: The Journal of hospital infection

Published: January 21, 2026

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.

Journal: Clinical genitourinary cancer

Published: December 17, 2025

Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts.

Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts.

Journal: BJU international

Published: December 15, 2025

Role of Vaginal Microbiota and Oral Lactobacillus Supplementation in Recurrent Urinary Tract Infections of Menopausal Women: Protocol for the VaMirUTI Cohort Study.

Role of Vaginal Microbiota and Oral Lactobacillus Supplementation in Recurrent Urinary Tract Infections of Menopausal Women: Protocol for the VaMirUTI Cohort Study.

Journal: Bioengineering (Basel, Switzerland)

Published: September 17, 2025

Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors.

Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors.

Journal: Journal of cancer research and clinical oncology

Published: August 06, 2025

Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.

Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 01, 2025

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

Journal: Clinical nuclear medicine

Published: July 08, 2025

Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer.

Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer.

Journal: European urology open science

Published: April 17, 2025

Correlation of HLA-A and HLA-B/C Expression With PD-1 and PD-L1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Survival.

Correlation of HLA-A and HLA-B/C Expression With PD-1 and PD-L1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Survival.

Journal: In vivo (Athens, Greece)

Published: December 22, 2024

Correlation of HLA-A and HLA-B/C Expression With ESR1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Distant Disease-free Survival.

Correlation of HLA-A and HLA-B/C Expression With ESR1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Distant Disease-free Survival.

Journal: Anticancer research

Published: December 22, 2024

Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.

Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.

Journal: Cancers

Published: December 08, 2024

Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.

Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.

Journal: Cancers

Published: December 05, 2024

Showing 1-12 of 136

Last Updated: 09/26/2026